Personal information

Keywords

breast cancer, metastasis, tumour heterogeneity, genomics, liquid biopsy, tumour microenviroment

Countries

Spain

Activities

Collapse all

Employment (2)

IrsiCaixa: Badalona, ES

2019-06-02 to present | Principal Investigator (NEOANTIGENS AND THERAPEUTIC VACCINES FOR CANCER )
Employment
Source: Self-asserted source
Leticia De Mattos-Arruda

Vall d´Hebron Institut d´Oncologia: Barcelona, ES

2017-01-01 to 2019-06-01 | Junior Principal Investigator / Group leader (Oncology)
Employment
Source: Self-asserted source
Leticia De Mattos-Arruda

Education and qualifications (6)

Cancer Research UK Cambridge Institute: Cambridge, GB

2015 to 2017 | Visiting research scientist (Carlos Caldas lab)
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Universitat Autònoma de Barcelona Facultat de Medicina: Bellaterra, Catalunya, ES

2013 to 2016 | PhD (Medicine)
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Memorial Sloan Kettering Cancer Center: New York, NY, US

2014 to 2015 | research fellow
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Hospital Vall d'Hebron: Barcelona, Catalunya, ES

2009-09 to 2014-02 | Postdoctoral training clinical research (Oncology )
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Universitat Autònoma de Barcelona Facultat de Medicina: Bellaterra, Catalunya, ES

2012 to 2013 | Masters
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Universidade Federal de Minas Gerais: Belo Horizonte, MG, BR

1999 to 2004 | Medical Doctor (Medicine )
Education
Source: Self-asserted source
Leticia De Mattos-Arruda

Professional activities (1)

European Society for Medical Oncology : Lugano, CH

2008 to present
Membership
Source: Self-asserted source
Leticia De Mattos-Arruda

Funding (6)

Leaders Generation Program of ESMO

2017 to present | Award
European Society for Medical Oncology (Lugano, CH)
Source: Self-asserted source
Leticia De Mattos-Arruda

Advanced Program in Oncology

2014 to 2015 | Salary award
Fundación Científica Asociación Española Contra el Cáncer (Madrid , ES)
Source: Self-asserted source
Leticia De Mattos-Arruda

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

2013 to present | Award
Conquer Cancer Foundation (VA, VA, US)
Source: Self-asserted source
Leticia De Mattos-Arruda

AACR Scholar-In-Training Award

2013 to present | Award
American Association for Cancer Research (PA, PA, US)
Source: Self-asserted source
Leticia De Mattos-Arruda

Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.

2012 to present | Award
Conquer Cancer Foundation (VA, VA, US)
Source: Self-asserted source
Leticia De Mattos-Arruda

ESMO translational fellowship

2010 to 2012 | Grant
European Society for Medical Oncology (Lugano, CH)
Source: Self-asserted source
Leticia De Mattos-Arruda

Works (37)

Clinical implications of intratumor heterogeneity: challenges and opportunities.

Journal of molecular medicine (Berlin, Germany)
2020-01 | Journal article
DOI: 10.1007/s00109-020-01874-2
PMID: 31970428
PMC: PMC7007907
Contributors: Ramón Y Cajal S; Sesé M; Capdevila C; Aasen T; De Mattos-Arruda L; Diaz-Cano SJ; Hernández-Losa J; Castellví J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.

Cell reports
2019-05 | Journal article
DOI: 10.1016/j.celrep.2019.04.098
PMID: 31141692
PMC: PMC6546974
Contributors: De Mattos-Arruda L; Sammut SJ; Ross EM; Bashford-Rogers R; Greenstein E; Markus H; Morganella S; Teng Y; Maruvka Y; Pereira B et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Critical reviews in oncology/hematology
2018-12 | Journal article
DOI: 10.1016/j.critrevonc.2018.12.004
PMID: 30771872
Contributors: Cristofanilli M; Pierga JY; Reuben J; Rademaker A; Davis AA; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Annals of oncology : official journal of the European Society for Medical Oncology
2018-11 | Journal article
DOI: 10.1093/annonc/mdx804
PMID: 29718117
PMC: PMC6887917
Contributors: Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

ESMO open
2018-08 | Journal article
DOI: 10.1136/esmoopen-2018-000368
PMID: 30167331
PMC: PMC6109817
Contributors: Preusser M; De Mattos-Arruda L; Thill M; Criscitiello C; Bartsch R; Ruhstaller T; de Azambuja E; Zielinski CC
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

News from ASCO 2018.

Breast care (Basel, Switzerland)
2018-07 | Journal article
DOI: 10.1159/000491564
PMID: 30319333
PMC: PMC6167691
Contributors: Balic M; Dedic N; De Mattos-Arruda L; Gampenrieder S
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

Oncotarget
2018-04 | Journal article
DOI: 10.18632/oncotarget.25041
PMID: 29755676
PMC: PMC5945519
Contributors: De Mattos-Arruda L; Ng CKY; Piscuoglio S; Gonzalez-Cao M; Lim RS; De Filippo MR; Fusco N; Schultheis AM; Ortiz C; Viteri S et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

ESMO Leaders Generation Programme: an alumni insight.

ESMO open
2018-01 | Journal article
DOI: 10.1136/esmoopen-2017-000312
PMID: 29464107
PMC: PMC5812397
Contributors: Arruda LM; Criscitiello C; Lambertini M; Argiles G
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid.

ESMO open
2017-10 | Journal article
DOI: 10.1136/esmoopen-2017-000270
PMID: 29067217
PMC: PMC5640134
Contributors: De Mattos-Arruda L
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Cancer as an ecomolecular disease and a neoplastic consortium.

Biochimica et biophysica acta. Reviews on cancer
2017-09 | Journal article
DOI: 10.1016/j.bbcan.2017.09.004
PMID: 28947238
Contributors: Ramón Y Cajal S; Capdevila C; Hernandez-Losa J; De Mattos-Arruda L; Ghosh A; Lorent J; Larsson O; Aasen T; Postovit LM; Topisirovic I
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

European journal of cancer (Oxford, England : 1990)
2017-07 | Journal article
DOI: 10.1016/j.ejca.2017.04.014
PMID: 28692951
Contributors: Aapro M; Astier A; Audisio R; Banks I; Bedossa P; Brain E; Cameron D; Casali P; Chiti A; De Mattos-Arruda L et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers.

Genome medicine
2017-04 | Journal article
DOI: 10.1186/s13073-017-0425-1
PMID: 28420412
PMC: PMC5394620
Contributors: Callari M; Sammut SJ; De Mattos-Arruda L; Bruna A; Rueda OM; Chin SF; Caldas C
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

The Genomic Landscape of Male Breast Cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research
2016-03 | Journal article
DOI: 10.1158/1078-0432.CCR-15-2840
PMID: 26960396
PMC: PMC4987160
Contributors: Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Translating neoadjuvant therapy into survival benefits: one size does not fit all.

Nature reviews. Clinical oncology
2016-03 | Journal article
DOI: 10.1038/nrclinonc.2016.35
PMID: 27000962
PMC: PMC5118200
Contributors: De Mattos-Arruda L; Shen R; Reis-Filho JS; Cortés J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.

Melanoma research
2015-12 | Journal article
DOI: 10.1097/cmr.0000000000000187
PMID: 26366702
Contributors: Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.

Molecular oncology
2015-12 | Journal article
DOI: 10.1016/j.molonc.2015.12.001
PMID: 26776681
PMC: PMC5528975
Contributors: De Mattos-Arruda L; Caldas C
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

Nature communications
2015-11 | Journal article
DOI: 10.1038/ncomms9839
PMID: 26554728
PMC: PMC5426516
Contributors: De Mattos-Arruda L; Mayor R; Ng CKY; Weigelt B; Martínez-Ricarte F; Torrejon D; Oliveira M; Arias A; Raventos C; Tang J et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

Oncotarget
2015-11 | Journal article
DOI: 10.18632/oncotarget.5495
PMID: 26452030
PMC: PMC4741929
Contributors: De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.

The Journal of pathology
2015-07 | Journal article
DOI: 10.1002/path.4566
PMID: 26011570
PMC: PMC5011405
Contributors: Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Are acinic cell carcinomas of the breast and salivary glands distinct diseases?

Histopathology
2015-03 | Journal article
DOI: 10.1111/his.12673
PMID: 25688711
PMC: PMC5006393
Contributors: Piscuoglio S; Hodi Z; Katabi N; Guerini-Rocco E; Macedo GS; Ng CK; Edelweiss M; De Mattos-Arruda L; Wen HY; Rakha EA et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Escaping out of the brain.

Cancer discovery
2014-11 | Journal article
DOI: 10.1158/2159-8290.cd-14-1178
PMID: 25367947
Contributors: Seoane J; De Mattos-Arruda L
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Brain metastasis: new opportunities to tackle therapeutic resistance.

Molecular oncology
2014-06 | Journal article
DOI: 10.1016/j.molonc.2014.05.009
PMID: 24953014
PMC: PMC5528619
Contributors: Seoane J; De Mattos-Arruda L
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast.

Molecular oncology
2014-06 | Journal article
DOI: 10.1016/j.molonc.2014.06.011
PMID: 25041824
PMC: PMC5037246
Contributors: Piscuoglio S; Ng CK; Martelotto LG; Eberle CA; Cowell CF; Natrajan R; Bidard FC; De Mattos-Arruda L; Wilkerson PM; Mariani O et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

The Lancet. Oncology
2014-03 | Journal article
DOI: 10.1016/s1470-2045(14)70069-5
PMID: 24636208
Contributors: Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Re: time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions.

Journal of the National Cancer Institute
2013-11 | Journal article
DOI: 10.1093/jnci/djt324
PMID: 24218522
Contributors: Di Cosimo S; de Mattos-Arruda L; Rubio I; Cortes J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.

Molecular oncology
2013-10 | Journal article
DOI: 10.1016/j.molonc.2013.10.006
PMID: 24220311
PMC: PMC5528499
Contributors: De Mattos-Arruda L; Bidard FC; Won HH; Cortes J; Ng CK; Peg V; Nuciforo P; Jungbluth AA; Weigelt B; Berger MF et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.

The oncologist
2013-10 | Journal article
DOI: 10.1634/theoncologist.2013-0135
PMID: 24136009
PMC: PMC3825301
Contributors: De Mattos-Arruda L; Rodon J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Cancer discovery
2013-08 | Journal article
DOI: 10.1158/2159-8290.cd-13-0132
PMID: 23950206
Contributors: Serra V; Vivancos A; Puente XS; Felip E; Silberschmidt D; Caratù G; Parra JL; De Mattos-Arruda L; Grueso J; Hernández-Losa J et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

Advances in therapy
2013-07 | Journal article
DOI: 10.1007/s12325-013-0043-2
PMID: 23881722
Contributors: De Mattos-Arruda L; Cortes J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Circulating tumour cells and cell-free DNA as tools for managing breast cancer.

Nature reviews. Clinical oncology
2013-05 | Journal article
DOI: 10.1038/nrclinonc.2013.80
PMID: 23712187
Contributors: De Mattos-Arruda L; Cortes J; Santarpia L; Vivancos A; Tabernero J; Reis-Filho JS; Seoane J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012-11 | Journal article
DOI: 10.1200/JCO.2012.44.2285
PMID: 23169515
PMC: PMC3530692
Contributors: Azim HA; Kroman N; Paesmans M; Gelber S; Rotmensz N; Ameye L; De Mattos-Arruda L; Pistilli B; Pinto A; Jensen MB et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Circulating tumour cells in early breast cancer.

The Lancet. Oncology
2012-09 | Journal article
DOI: 10.1016/s1470-2045(12)70316-9
PMID: 22935235
Contributors: De Mattos-Arruda L; Tabernero J; Seoane J; Cortes J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Progress against solid tumors in danger: the metastatic breast cancer example.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012-08 | Journal article
DOI: 10.1200/JCO.2012.41.9580
PMID: 22927522
PMC: PMC6076005
Contributors: Cortés J; Calvo E; González-Martín A; Dawood S; Llombart-Cussac A; De Mattos-Arruda L; Gómez P; Silva O; Perez EA; Rugo HS et al.
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

Breast (Edinburgh, Scotland)
2012-05 | Journal article
DOI: 10.1016/j.breast.2012.04.002
PMID: 22560618
Contributors: De Mattos-Arruda L; Cortes J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.

The oncologist
2012-04 | Journal article
DOI: 10.1634/theoncologist.2011-0187
PMID: 22523199
PMC: PMC3360903
Contributors: De Mattos-Arruda L; Cortes J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer.

Future oncology (London, England)
2011-12 | Journal article
DOI: 10.2217/fon.11.122
PMID: 22112315
Contributors: De Mattos-Arruda L; Olmos D; Tabernero J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Development of molecular biomarkers in individualized treatment of colorectal cancer.

Clinical colorectal cancer
2011-05 | Journal article
DOI: 10.1016/j.clcc.2011.03.030
PMID: 21729679
Contributors: De Mattos-Arruda L; Dienstmann R; Tabernero J
Source: Self-asserted source
Leticia De Mattos-Arruda via Europe PubMed Central

Peer review (3 reviews for 2 publications/grants)

Review activity for Nature communications (1)
Review activity for NPJ breast cancer. (2)
How many people are using ORCID?